Promises of eukaryotic ribonucleases for cancer treatment: a systematic review

Translational Medicine Communications
Yesuf Adem Siraj1,2
1Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
2Department of Medical Laboratory Sciences, School of Health Sciences, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia

Tóm tắt

Abstract Background Following an increasing interest in exploration of anticancer chemotherapeutic agents, ribonucleases are currently under investigations for alternative anticancer chemotherapy. Objective The current review scrutinizes information on the potential capability of eukaryotic ribonucleases for cancer treatment. Methods Predefined searching terms were applied to PubMed, Scopus, eLibrary databases and other search engines such as Google Scholar and bioRvix preprints. Twenty four research articles on eukaryotic ribonuclease were included in the review. Qualitative and quantitative information of these studies were extracted, analyzed and explained in text, tables and figures. Results Majority of eukaryotic ribonucleases (46%, 11/24) included in the review were extracted from various species of frogs, 21% (5/24) were from bovine sources and others were from human bodies, edible mushrooms, fungal and plant species. Molecular characteristics of eukaryotic ribonucleases were illustrated in tables and figures. According to the reports, ranpirnase with a trademark of Onconase® is the sole ribonuclease granted with an orphan and fast-track drug status by FDA, USA. Most other eukaryotic ribonucleases are undergoing various preclinical stages of research for their potential anticancer effect. Hence, the mean of half – maximal inhibitory concentrations (IC50) of eukaryotic ribonucleases of several research outcomes showed their selective cytotoxicity towards cancerous cells. In some reports, pre-tumor-xenografted animals treated with ribonucleases also demonstrated diminished tumor volume, lower tumor metastasis and increased survival rates. In addition, overall safety and toxicity parameters were also indicated as tolerable by the experimental hosts. However, a single study indicated degeneration of spermatogenic epithelia in wheat leave RNase treated animals. Conclusions Though several clinical trials on eukaryotic ribonucleases are expected, existing results from in vitro and in vivo preclinical studies showed promising alternative chemotherapy to treat cancer diseases. Hence, further human safety and efficacy studies are still necessary to explore well established applications of eukaryotic ribonucleases in clinical medicine.

Từ khóa


Tài liệu tham khảo

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.

Matousek J, Matousek J. Plant ribonucleases and nucleases as antiproliferative agens targeting human tumors growing in mice. Recent Pat DNA Gene Seq. 2010;4(1):29–39.

FDA. https://www.fda.gov/media/76409/download. 2009. Accessed 5 Jan 2021.

Ardelt W, Ardelt B, Darzynkiewicz Z. Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol. 2009;625(1–3):181–9.

Benito A, Ribó M, Vilanova M. On the track of antitumour ribonucleases. Mol Biosyst. 2005;1(4):294–302.

Irie M, Nitta K, Nonaka T. Biochemistry of frog ribonucleases. Cell Mol Life Sci. 1998;54(8):775–84.

Matousek J. Ribonucleases and their antitumor activity. Comp Biochem Physiol C Toxicol Pharmacol. 2001;129(3):175–91.

Kurinenko BM. Antitumor activity of ribonucleases. Eksp Onkol. 1985;7(2):3–8.

The UC. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2017;45(D1):D158–69.

Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, et al. Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res. 2008;36(Web Server issue):W465–9.

Laccetti P, Portella G, Mastronicola MR, Russo A, Piccoli R, D’Alessio G, et al. In vivo and in vitro growth-inhibitory effect of bovine seminal ribonuclease on a system of rat thyroid epithelial transformed cells and tumors. Cancer Res. 1992;52(17):4582–6.

Laccetti P, Spalletti-Cernia D, Portella G, De Corato P, D’Alessio G, Vecchio G. Seminal ribonuclease inhibits tumor growth and reduces the metastatic potential of Lewis lung carcinoma. Cancer Res. 1994;54(16):4253–6.

Poucková P, Soucek J, Matousek J, Zadinová M, Hlousková D, Polívková J, et al. Antitumor action of bovine seminal ribonuclease. Folia Microbiol (Praha). 1998;43(5):511–2.

Di Liddo R, Dalzoppo D, Baiguera S, Conconi MT, Dettin M, Parnigotto PP, et al. In vitro biological activity of bovine milk ribonuclease-4. Mol Med Rep. 2010;3(1):127–32.

Patutina O, Mironova N, Ryabchikova E, Popova N, Nikolin V, Kaledin V, et al. Inhibition of metastasis development by daily administration of ultralow doses of RNase A and DNase I. Biochimie. 2011;93(4):689–96.

Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet. 1988;21(3):169–82.

Vasandani VM, Burris JA, Sung C. Reversible nephrotoxicity of onconase and effect of lysine pH on renal onconase uptake. Cancer Chemother Pharmacol. 1999;44(2):164–9.

Lee I, Lee YH, Mikulski SM, Lee J, Covone K, Shogen K. Tumoricidal effects of onconase on various tumors. J Surg Oncol. 2000;73(3):164–71.

Vogelzang NJ, Aklilu M, Stadler WM, Dumas MC, Mikulski SM. A phase II trial of weekly intravenous ranpirnase (Onconase®), a novel ribonuclease in patients with metastatic kidney cancer.  Invest New Drugs. 2001;19(3):255–60.

Magnitsky S, Sunar U, Milkevitch M, Yodh A, Lee I, editors. Ranpirnase-induced changes in blood flow, lactate, and ATP levels in A549 human NSCLC measured by noninvasive near infrared spectroscopy and magnetic resonance spectroscopy. 14th. Int Soc Magn Reson Med; 2006.

Lee I, Kim DH, Sunar U, Magnitsky S, Shogen K. The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo. 2007;21(5):721–8.

Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol. 2001;20(1):274–81.

Smolewski P, Witkowska M, Zwolinska M, Cebula-Obrzut B, Majchrzak A, Jeske A, et al. Cytotoxic activity of the amphibian ribonucleases onconase and r-amphinase on tumor cells from B cell lymphoproliferative disorders. Int J Oncol. 2014;45(1):419–25.

Ardelt B, Ardelt W, Pozarowski P, Kunicki J, Shogen K, Darzynkiewicz Z. Cytostatic and cytotoxic properties of Amphinase: a novel cytotoxic ribonuclease from Rana pipiens oocytes. Cell Cycle. 2007;6(24):3097–102.

Liao YD, Huang HC, Leu YJ, Wei CW, Tang PC, Wang SC. Purification and cloning of cytotoxic ribonucleases from Rana catesbeiana (bullfrog). Nucleic Acids Res. 2000;28(21):4097–104.

Wang Z, Lin F, Liu J, Qiu F. A Novel Ribonuclease from Rana Chensinensis and Its Potential for the Treatment of Human Breast Cancer. Cancer Biother Radiopharm. 2015;30(9):380–5.

Griffiths SJ, Adams DJ, Talbot SJ. Ribonuclease inhibits Kaposi’s sarcoma. Nature. 1997;390(6660):568.

Maeda T, Mahara K, Kitazoe M, Futami J, Takidani A, Kosaka M, et al. RNase 3 (ECP) is an extraordinarily stable protein among human pancreatic-type RNases. J Biochem. 2002;132(5):737–42.

Castro J, Ribó M, Navarro S, Nogués MV, Vilanova M, Benito A. A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation. BMC Cancer. 2011;11:9.

Zhang RY, Zhang GQ, Hu DD, Wang HX, Ng TB. A novel ribonuclease with antiproliferative activity from fresh fruiting bodies of the edible mushroom Lyophyllum shimeiji. Biochem Genet. 2010;48(7–8):658–68.

Joseph TP, Zhao Q, Chanda W, Kanwal S, Fang Y, Zhong M, et al. Expression and in vitro anticancer activity of Lp16-PSP, a member of the YjgF/YER057c/UK114 protein family from the mushroom Lentinula edodes C91–3. 2020.

Kumar GR, Chikati R, Pandrangi SL, Kandapal M, Sonkar K, Gupta N, et al. Molecular docking and dynamics simulations of A.niger RNase from Aspergillus niger ATCC26550: for potential prevention of human cancer. J Mol Model. 2013;19(2):613–21.

Skvor J, Lipovová P, Poucková P, Soucek J, Slavík T, Matousek J. Effect of wheat leaf ribonuclease on tumor cells and tissues. Anticancer Drugs. 2006;17(7):815–23.

Fang EF, Zhang CZ, Zhang L, Fong WP, Ng TB. In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. Int J Biochem Cell Biol. 2012;44(8):1351–60.

Mironova N, Vlassov V. Surveillance of Tumour Development: The Relationship Between Tumour-Associated RNAs and Ribonucleases. Front Pharmacol. 2019;10:1019.

Lee JE, Raines RTJB. Ribonucleases as novel chemotherapeutics. 2008;22(1):53–8.

Ardelt W, Shogen K, Darzynkiewicz Z. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes. Curr Pharm Biotechnol. 2008;9(3):215–25.

Lee I. Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Expert Opin Biol Ther. 2008;8(6):813–27.

Lee I, Kalota A, Gewirtz AM, Shogen K. Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res. 2007;27(1A):299–307.

Soucek J, Skvor J, Poucková P, Matousek J, Slavík T, Matousek J. Mung bean sprout (Phaseolus aureus) nuclease and its biological and antitumor effects. Neoplasma. 2006;53(5):402–9.

Arnold U, Ulbrich-Hofmann R. Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett. 2006;28(20):1615–22.

Aravind L. and Koonin E. A Natural Classification of Ribonucleases. In: Ribonuclease Classification and Review; Methods in Enzymology. Academic Press. 2001;341:3–28.

Condon C. RNA Processing. In: Schaechter M, editor. Encyclopedia of Microbiology. 3rd ed. Oxford: Academic Press; 2009. p. 95–408.

Attery A, Batra JK. Mouse eosinophil associated ribonucleases: Mechanism of cytotoxic, antibacterial and antiparasitic activities. Int J Biol Macromol. 2017;94:445–50.

Hameş EE, Demir T. Microbial ribonucleases (RNases): production and application potential. World J Microbiol Biotechnol. 2015;31(12):1853–62.

Ilinskaya ON, Zelenikhin PV, Petrushanko IY, Mitkevich VA, Prassolov VS, Makarov AA. Binase induces apoptosis of transformed myeloid cells and does not induce T-cell immune response. Biochem Biophys Res Commun. 2007;361(4):1000–5.

Dudkina E, Ulyanova V, Shah Mahmud R, Khodzhaeva V, Dao L, Vershinina V, et al. Three-step procedure for preparation of pure Bacillus altitudinis ribonuclease. FEBS Open Bio. 2016;6(1):24–32.

Makarov AA, Kolchinsky A, Ilinskaya ON. Binase and other microbial RNases as potential anticancer agents. BioEssays. 2008;30(8):781–90.

Mitkevich VA, Pace CN, Koschinski A, Makarov AA, Ilinskaya ON. Cytotoxicity mechanism of the RNase Sa cationic mutants involves inhibition of potassium current through Ca2+-activated channels. Mol Biol (Mosk). 2015;49(6):1041–7.

Fang EF, Ng TB. Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta. 2011;1815(1):65–74.

Sokurenko Y, Nadyrova A, Ulyanova V, Ilinskaya O. Extracellular Ribonuclease from Bacillus licheniformis (Balifase), a New Member of the N1/T1 RNase Superfamily. Biomed Res Int. 2016;2016:4239375.

Ulyanova V, Vershinina V, Ilinskaya O. Barnase and binase: twins with distinct fates. Febs j. 2011;278(19):3633–43.

Shruti G, Sukhdev S, Singh KS. Purification and characterization of an extracellular ribonuclease from a Bacillus sp. RNS3 (KX966412). Int J Biol Macromol. 2017;97:440–6.

Kanlayakrit W, Ikeda T, Tojai S, Rodprapakorn M, Sirisansaneeyakul S. Isolation and Characterization of Extracellular Halophilic Ribonuclease from Halotolerant Pseudomonas species. Nat Sci. 2001;35:179–87.

Costanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest. 2005;23(7):643–50.

Kanwar SS, Mishra P, Meena KR, Gupta S, Kumar R. Ribonucleases and thier Applications. Journal of Advanced Biotechnology and Bioengineering. 2016;4:17–26.

Reck M, Krzakowski M, Jassem J, Eschbach C, Kozielski J, Costanzi J, et al. Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM). Journal of Clinical Oncology. 2009;27(15 Suppl):7507.

Zelenikhin P, Makeeva A, Nguen T, Siraj Y. Ilinskaya OJBk. Combined action of binase and bleomycin toward human lung adenocarcinoma cells. 2016;62(3):279–82.

Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics. 2008;2(4):601–9.

Majchrzak A, Witkowska M, Mędra A, Zwolińska M, Bogusz J, Cebula-Obrzut B, et al. In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line. Postepy Hig Med Dosw  (Online). 2013;67:1166–72.

Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL, et al. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J Natl Cancer Inst. 1996;88(11):747–53.

Shen R, Li J, Ye D, Wang Q, Fei J. Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma. Acta Biochim Biophys Sin (Shanghai). 2016;48(10):894–901.

Shirshikov FV, Cherepnev GV, Ilinskaya ON, Kalacheva NV. A hydrophobic segment of some cytotoxic ribonucleases. Med Hypotheses. 2013;81(2):328–34.

Isom DG, Castaneda CA, Cannon BR, Velu PD, Garcia-Moreno EB. Charges in the hydrophobic interior of proteins. Proc Natl Acad Sci U S A. 2010;107(37):16096–100.

Stewart KL, Rathore D, Dodds ED, Cordes MHJ. Increased sequence hydrophobicity reduces conformational specificity: A mutational case study of the Arc repressor protein. Proteins. 2019;87(1):23–33.

Ardelt B, Ardelt W, Darzynkiewicz Z. Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle. 2003;2(1):22–4.

Beck AK, Pass HI, Carbone M, Yang H. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies. Future Oncol. 2008;4(3):341–9.

Ardelt B, Juan G, Burfeind P, Salomon T, Wu J, Hsieh T, et al. Onconase, an anti-tumor ribonuclease suppresses intracellular oxidative stress. International journal of oncology. 2007;31(3):663–9.

Lu CX, Nan KJ, Lei Y. Agents from amphibians with anticancer properties. Anticancer Drugs. 2008;19(10):931–9.

Shen R, Ye D, Huang Q, Li J, Wang Q, Fei J. An EGF receptor-targeting amphinase recombinant protein mediates anti-tumor activity in vitro and in vivo. Acta Biochim Biophys Sin (Shanghai). 2018;50(4):391–8.

Castro J, Ribó M, Vilanova M, Benito A. Strengths and Challenges of Secretory Ribonucleases as AntiTumor Agents. Pharmaceutics. 2021;13(1):82.

Alfacell Corporation U. Alfacell Corporation Announces Preliminary Results from ONCONASE® Phase IIIb Clinical Trial. 2008. https://www.sec.gov/Archives/edgar/data/708717/000093041308003481/c53793_ex99-1.htm. Accessed 21 Jan 2021.

Mikulski SM, Grossman AM, Carter PW, Shogen K, Costanzi JJ. Phase-I Human Clinical-Trial of Onconase® (P-30 Protein) Administered Intravenously on a Weekly Schedule In Cancer-Patients With Solid Tumors. Int J Oncol. 1993;3(1):57–64.

Thông tin
Thông tin xuất bản

Translational Medicine Communications

Thông tin tác giả